• 1. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 2. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 3. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 4. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
• 5. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives
• Solvents and Organic Chemicals Organic Compounds Acids/Esters

Recent Advances in the Study of 2-acetamido-3-(4-hydroxyphenyl)propanoic acid (CAS: 2901-77-1) in Chemical Biology and Pharmaceutical Research

The compound 2-acetamido-3-(4-hydroxyphenyl)propanoic acid (CAS: 2901-77-1) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This molecule, characterized by its unique structural features, has been the subject of several studies aimed at exploring its potential applications in drug development and therapeutic interventions. The presence of both acetamido and hydroxyphenyl groups in its structure makes it a promising candidate for modulating biological pathways, particularly those involved in inflammation and metabolic disorders.

Recent research has focused on the synthesis and characterization of 2-acetamido-3-(4-hydroxyphenyl)propanoic acid, with an emphasis on optimizing its yield and purity. Advanced spectroscopic techniques, including NMR and mass spectrometry, have been employed to confirm the structural integrity of the compound. Additionally, computational modeling studies have provided insights into its molecular interactions, suggesting potential binding affinities with various biological targets. These findings are crucial for understanding the compound's mechanism of action and its potential as a lead molecule in drug discovery.

In vitro and in vivo studies have further elucidated the pharmacological properties of 2-acetamido-3-(4-hydroxyphenyl)propanoic acid. Preliminary results indicate that the compound exhibits anti-inflammatory and antioxidant activities, making it a viable candidate for treating conditions such as rheumatoid arthritis and neurodegenerative diseases. Moreover, its metabolic stability and low toxicity profile, as demonstrated in preclinical models, underscore its potential for further development into a therapeutic agent. Researchers are now exploring its efficacy in combination therapies, aiming to enhance its therapeutic outcomes while minimizing adverse effects.

The integration of 2-acetamido-3-(4-hydroxyphenyl)propanoic acid into drug delivery systems has also been a focal point of recent investigations. Nanoparticle-based formulations have shown promise in improving the compound's bioavailability and targeted delivery to specific tissues. These advancements are expected to address some of the challenges associated with its pharmacokinetic properties, thereby accelerating its transition from bench to bedside. Collaborative efforts between academic institutions and pharmaceutical companies are underway to scale up production and conduct clinical trials, paving the way for its eventual commercialization.

In conclusion, the growing body of research on 2-acetamido-3-(4-hydroxyphenyl)propanoic acid (CAS: 2901-77-1) highlights its potential as a multifaceted therapeutic agent. Its unique chemical properties, coupled with promising preclinical data, position it as a valuable asset in the quest for novel treatments for a range of diseases. Continued exploration of its biological activities and optimization of its formulations will be critical in realizing its full therapeutic potential. As the field progresses, this compound is poised to make significant contributions to the advancement of chemical biology and pharmaceutical sciences.

• 2018-61-3(N-Acetyl-L-phenylalanine)
• 2901-75-9(Afalanine)
• 17355-18-9(Phe-Tyr-OH)
• 17355-11-2(H-Tyr-Phe-OH)
• 10172-89-1(N-Acetyl-D-phenylalanine)
• 537-49-5(N-Methyl-L-tyrosine)
• 537-55-3(N-Acetyl-L-tyrosine)
• 17343-07-6(Glycylglycyl-L-tyrosine)
• 19764-32-0(Ac-D-Tyr-OH)
• 658-79-7(Glycyl-L-tyrosine)